Form 4: ResMed CEO Michael Farrell Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock on July 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 8, 2024, Michael J. Farrell, the CEO of ResMed Inc., executed options to acquire 14,683 shares of ResMed Common Stock at a price of $84.98.
- Concurrently, Farrell sold 14,683 shares of ResMed Common Stock at a weighted average price of $192.9667, with individual sales prices ranging from $192.03 to $194.73.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on January 31, 2024.
- Following these transactions, Farrell directly owns 440,799 shares of ResMed Common Stock.
- Farrell also indirectly owns 4,090 shares through the Lisette and Michael Farrell Foundation and the Lisette and Michael Farrell Family Trust.
- After the transaction, Farrell directly owns 58,732 ResMed Common Stock Options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine stock transactions under a pre-existing plan. There is no indication of positive or negative implications for the company's performance.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Rule 10b5-1 plans are frequently used to allow insiders to sell shares over time while avoiding accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- The use of Rule 10b5-1 plans is a standard practice among executives at publicly traded companies like ResMed, such as competitors like Philips or Fisher & Paykel Healthcare, to manage their stock holdings in a compliant manner.
- The size and frequency of these transactions are typical for CEOs of companies with ResMed's market capitalization.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely to be minimal given the relatively small number of shares involved compared to the total outstanding shares.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2018-11-11 | Date options first became exercisable. |
| 2024-01-31 | Date the Rule 10b5-1 plan was adopted. |
| 2024-07-08 | Date of the stock option exercise and share sale. |
| 2024-07-09 | Date of the Form 4 filing. |
| 2024-11-16 | Expiration date of the ResMed Common Stock Options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.